Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Trial ID or NCT#
Status
NOT RECRUITING
Purpose
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.
Official Title
An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Ann Moffat
669-233-2816
Contact us to find out if this trial is right for you.
Contact
Ann Moffat
669-233-2816
View on ClinicalTrials.gov
